Loading
An Indian phase 1 trial gave a worm medicine to 11 people with recurrent glioblastoma alongside chemotherapy or re-irradiation, found the dose they could tolerate, and saw anaemia and nausea as the most common side effects.
Eleven patients with recurrent glioblastoma were enrolled in an accelerated titration design: arm A1 added mebendazole to re-irradiation with concurrent temozolomide, arm B1 to lomustine and arm C1 to temozolomide alone (Reverse swing-M phase 1 2020). The maximum tolerated dose was not reached in arms A1 and C1, giving a recommended phase 2 dose of 1600 mg three times a day, while with lomustine it was 1600 mg three times a day and the recommended dose 800 mg three times a day; the most common adverse events were anaemia in 9 patients, nausea in 7 and fatigue in 6 (Reverse swing-M phase 1 2020).
This is what legitimate repurposing looks like: a registered dose-finding trial that reports its toxicities. It says nothing yet about whether mebendazole helps glioblastoma.
Shares Mebendazole, Systematic drug repurposing.
Shares Recommended phase 2 dose (RP2D), Dose-escalation designs (3+3, BOIN, dose-expansion).
Shares Lomustine (CCNU), Glioma & glioblastoma.
Shares Lomustine (CCNU), Temozolomide, Glioma & glioblastoma.
Shares Lomustine (CCNU), Temozolomide, Glioma & glioblastoma.
Shares Recommended phase 2 dose (RP2D), Dose-escalation designs (3+3, BOIN, dose-expansion).
Shares Temozolomide, Glioma & glioblastoma.
Shares Temozolomide, Glioma & glioblastoma.